|
Monday, January 17, 2022 |
|
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium |
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: LENVIMA, the orally available kinase inhibitor, 'lenvatinib") will be given at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI22), taking place in-person in San Francisco, California, and virtually, from January 20 to 22, 2022. more info >> |
|
Thursday, January 13, 2022 |
|
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health) |
Eisai Co., Ltd. announced today that its Taiwanese subsidiary Eisai Taiwan Inc. and Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. have launched "CogMateTM", a digital tool (non-medical device) for self-assessment of brain performance (brain health). more info >> |
|
Thursday, January 6, 2022 |
|
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator |
Eisai Co., Ltd. announced today that it has entered into a License Agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent H3B-8800 to a subsidiary of Roivant Sciences Ltd. more info >> |
|
Friday, December 24, 2021 |
|
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation |
Eisai Co., Ltd. and Biogen Inc. announced today that lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early Alzheimer's disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
Tuesday, December 21, 2021 |
|
Biogen Announces Reduced Price for Aduhelm to Improve Access For Patients With Early Alzheimer's Disease In The United States |
Eisai Co., Ltd. announced today that, effective January 1, 2022, Biogen will reduce the wholesale acquisition cost (WAC) of ADUHELM (aducanumab-avwa) 100 mg/mL injection for intravenous use in the United States by approximately 50%. For a patient of average weight (74 kg), the yearly cost at the maintenance dose (10 mg/kg) will be $28,200. more info >> |
|
Monday, December 20, 2021 |
|
Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia |
Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib. more info >> |
|
Monday, December 6, 2021 |
|
Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium |
Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates on its in-house discovered eribulin mesylate (product name: Halaven, halichondrin class microtubule dynamics inhibitor, "eribulin"), MORAb-202, an antibody drug conjugate (ADC), and H3B-6545 (selective estrogen alpha receptor covalent antagonist). more info >> |
|
Tuesday, November 30, 2021 |
|
Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia |
Eisai Co., Ltd. and FCNT LIMITED announced today that both companies have entered into a business alliance agreement aiming to support people living with dementia and to prevent dementia, through developing solutions for maintaining brain performance. more info >> |
|
Eisai to Present Latest Data on Perampanel and E2730 at the 75th American Epilepsy Society Annual Meeting |
Eisai Co., Ltd. announced today that the company will conduct a total of 42 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) and in-house discovered and developed E2730 at the 75th American Epilepsy Society Annual Meeting (AES2021), to be held in Chicago, Illinois and virtually from December 3 to 7, 2021. more info >> |
|
Monday, November 29, 2021 |
|
European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Patients With Certain Types of Endometrial Carcinoma |
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the European Commission has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
|
|